Market Research Logo

Non-Small Cell Lung Cancer Pipeline Highlights – 2017 Update

Non-Small Cell Lung Cancer Pipeline Highlights – 2017 Update

The latest report from Fore Pharma, Non-Small Cell Lung Cancer Pipeline Highlights – 2017 Update, provides most up-to-date information on key pipeline products in the global Non-Small Cell Lung Cancer market. It covers emerging therapies for Non-Small Cell Lung Cancer in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.

Clinical Trial Stages:
The report provides Non-Small Cell Lung Cancer pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Drug Mechanism Classes:
The report provides Non-Small Cell Lung Cancer pipeline products by their dominant mechanism of action. This helps executives categorize products based on their drug class and also assess the strengths and weaknesses of compounds.

Company:
The report provides Non-Small Cell Lung Cancer pipeline products by the company.

Short-term Launch Highlights:
Find out which Non-Small Cell Lung Cancer pipeline products will be launched in the US and Ex-US till 2020.

SUMMARY:

  • Non-Small Cell Lung Cancer phase 3 clinical trial pipeline products
  • Non-Small Cell Lung Cancer phase 2 clinical trial pipeline products
  • Non-Small Cell Lung Cancer phase 1 clinical trial pipeline products
  • Non-Small Cell Lung Cancer preclinical research pipeline products
  • Non-Small Cell Lung Cancer discovery stage pipeline products
  • Non-Small Cell Lung Cancer pipeline products short-term launch highlights


1. Non-Small Cell Lung Cancer Pipeline by Stages
2. Non-Small Cell Lung Cancer Pipeline by Drug Class
3. Non-Small Cell Lung Cancer Pipeline by Company
4. Non-Small Cell Lung Cancer Phase 3 Clinical Trial Insights
5. Non-Small Cell Lung Cancer Phase 2 Clinical Trial Insights
6. Non-Small Cell Lung Cancer Phase 1 Clinical Trial Insights
7. Non-Small Cell Lung Cancer Preclinical Research Insights
8. Non-Small Cell Lung Cancer Discovery Stage Insights
9. Appendix
10. Research Methodology
LIST OF TABLES
Table 1: Non-Small Cell Lung Cancer Phase 3 Clinical Trials, 2017
Table 2: Non-Small Cell Lung Cancer Phase 2 Clinical Trials, 2017
Table 3: Non-Small Cell Lung Cancer Phase 1 Clinical Trials, 2017
Table 4: Non-Small Cell Lung Cancer Preclinical Research, 2017
Table 5: Non-Small Cell Lung Cancer Discovery Stage, 2017
LIST OF FIGURES
Figure 1: Non-Small Cell Lung Cancer Pipeline Molecules by Clinical Trials Stage, 2017
Figure 2: Non-Small Cell Lung Cancer Pipeline Molecules by Drug Class, 2017
Figure 3: Non-Small Cell Lung Cancer Pipeline Molecules by Company, 2017
Figure 4: Non-Small Cell Lung Cancer Phase 3 Clinical Trial Highlights, 2017
Figure 5: Non-Small Cell Lung Cancer Phase 2 Clinical Trial Highlights, 2017
Figure 6: Non-Small Cell Lung Cancer Phase 1 Clinical Trial Highlights, 2017
Figure 7: Non-Small Cell Lung Cancer Preclinical Research Highlights, 2017
Figure 8: Non-Small Cell Lung Cancer Discovery Stage Highlights, 2017

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report